732 followers
Disappointing results from STEADFAST, a phase 3 study of Azeliragon (TTP488) in #Alzheimer's disease. Not surprising given its history. $VTVT https://t.co/wJje1fPpcc https://t.co/BDJQfvH1wl https://t.co/nyOXNmNvfT https://t.co/fNW2ib5Vg8